Tatsuya Ikeda has extensive professional experience in the finance and business development fields. Tatsuya began their career in 2000 as a Financial Analyst at Goldman Sachs. In 2003, they joined GE Capital Real Estate, where they held several roles including Investment Manager, Manager, Associate Director - North America Lending, Business Development, Associate Director - North America Equity, Venture Investments, Associate Director - Asia Pacific Business Development, and Associate Director - Asia Pacific Structured Finance. In 2011, they became the Managing Director of Delta Capital Investments. In 2017, they joined SmartRyde as Director and Chief Financial Officer, where they were responsible for corporate finance and looking for OTAs, travel agencies, airlines, travel activity companies, card companies and others to work together. In 2018, they became President and Representative Director of Precision Medicine Asia Co. Ltd., providing prominent and dedicated services in the oncological precision medicine field. In 2021, they became Director and Chief Operating Officer of PREMIA Holdings.
Tatsuya Ikeda has an extensive educational background. Tatsuya earned their MBA in Finance from NYU Stern School of Business between 2007 and 2009. Tatsuya also obtained a BA in Management and Finance from Hitotsubashi University between 1995 and 1999. In 2020, they completed an HMX Fundamentals/Pro online certificate program in Cancer Genomics and Precision Oncology from Harvard Medical School. In 2021, they completed an HMX Fundamentals/Pro - Genetics - Genetic Testing and Sequencing Technologies from Harvard Medical School.
August, 2017 - present